nontuberculous mycobacteria
SusceptibilityIn Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus ComplexWe performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 104 nonduplicate isolates of Mycobacterium abscessus complex [M. abscessus subsp. abscessus...
SusceptibilityWhole-Genome Sequencing for Predicting Clarithromycin Resistance in Mycobacterium abscessusMycobacterium abscessus is emerging as an important pathogen in chronic lung diseases, with concern regarding patient-to-patient transmission. The recent introduction of routine whole-genome sequencing (WGS) as a replacement for existing reference techniques in England provides an opportunity to characterize the genetic determinants of resistance.
SusceptibilityIn Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous MycobacteriaNontuberculous mycobacterium (NTM) infections are increasing globally. The Mycobacterium avium complex (MAC) and Mycobacterium abscessus are the most frequently encountered NTM among clinical laboratories, and treatment options are extremely limited.
Clinical TherapeuticsNontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus ComplexMycobacterium avium complex (MAC) and M. abscessus complex (MABC) comprise the two most important human pathogen groups causing nontuberculous mycobacterial lung disease (NTM-LD). However, there are limited data regarding NTM-LD caused by mixed NTM infections.
- Clinical TherapeuticsClofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease